Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Pak J Pharm Sci ; 37(1(Special)): 215-222, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38747272

ABSTRACT

This study was aimed to assess the type and severity of COVID vaccine-induced menstrual disorders and also to investigate the risk factors for menstrual changes following COVID-19 vaccination in Pakistani females. A cross-sectional survey-based study was conducted in females between 12 -70 years of age from February to July 2022. The survey was conducted via in-person interviews as well as via social media. The data was analyzed using standard descriptive statistical parameters, the sociodemographic and clinical features were evaluated and reported as frequencies (percentages). The study comprised a total of 1023 female subjects. Approximately 36.9% of women reported menstrual abnormalities following immunization, with 30.5% experiencing them following their second dose. However, in majority of these women (21%) the symptoms were resolved after 3 months of irregularity. Vaccine type significantly influenced the incidence of menstrual disorders (p <0.001) which were linked to Pfizer-Biontech, Sinopahrm, Sinovac, Moderna at rates of 14.9%, 9.5%, 4.7% and 2.7%, respectively. Both AstraZeneca and Moderna were implicated in postmenopausal bleeding (1.6% and 0.8%, respectively). The study showed that females receiving COVID-19 vaccines experienced menstrual irregularities such as short duration of periods, decreased volume of bleeding, and frequent menstrual cycles. However, the symptoms were temporary and self-limiting.


Subject(s)
COVID-19 Vaccines , COVID-19 , Menstruation Disturbances , Humans , Female , Cross-Sectional Studies , Pakistan/epidemiology , Adult , COVID-19 Vaccines/adverse effects , COVID-19 Vaccines/administration & dosage , Adolescent , Middle Aged , Young Adult , COVID-19/prevention & control , COVID-19/epidemiology , Menstruation Disturbances/epidemiology , Aged , Child , Risk Factors , SARS-CoV-2/immunology , Vaccination/adverse effects
2.
Inflammopharmacology ; 31(6): 3281-3301, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37864683

ABSTRACT

Solanum nigrum L. is a popular traditional medicine for various inflammatory conditions including rheumatism and joint pain. The current study aimed to evaluate the anti-arthritic mechanism of Solanum nigrum L. Four extracts were prepared using n-hexane, methanol, chloroform, and water. The anti-nociceptive and anti-inflammatory activity was carried out with 100, 200, and 300 mg/kg body wt. PO of each extract by the hot plate and carrageenan-induced paw oedema methods, respectively. The anti-arthritic study was performed with chloroform and aqueous extracts (300 mg/kg) in complete Freund's adjuvant (CFA)-induced arthritis. Paw size (mm), ankle joint diameter (mm), and latency time (sec) were recorded on day 0 and every 4th day till 28 days. The hematological, inflammatory, and oxidative biomarkers were estimated. Results showed that significant analgesia (p < 0.05) and reduction in paw inflammation were achieved with all extracts. The highest percent inhibition in Carrageenan-induced inflammation was achieved with 300 mg/kg of chloroform (72.19%) and aqueous (71.30%) extracts, respectively. In the CFA model, both extracts showed a significant reduction in paw size and ankle joint diameter (p < 0.05). The RT-qPCR analysis revealed the upregulation of interleukin-4 and interleukin-10, and down-expression of interleukin-1ß, interleukin-6, tumor necrosis factor-α, cycloxygenase-2, nuclear factor-κB, prostaglandin E synthase 2, and interferon-γ. A significant increase in superoxide dismutase, catalase, and glutathione levels was observed. Hence, it is concluded that Solanum nigrum L. leaf extracts regulate the expression of inflammatory markers and improve oxidative stress resulting in the attenuation of CFA-induced arthritis.


Subject(s)
Arthritis, Experimental , Solanum nigrum , Animals , Cytokines/metabolism , Carrageenan , Antioxidants/pharmacology , Solanum nigrum/metabolism , Plant Extracts/pharmacology , Freund's Adjuvant , Chloroform/adverse effects , Arthritis, Experimental/chemically induced , Arthritis, Experimental/drug therapy , Arthritis, Experimental/pathology , Inflammation/drug therapy
3.
Heliyon ; 9(4): e14660, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37064443

ABSTRACT

Cassia absus, a member of Fabaceae family, has been a part of traditional medicine for various ailments such as Hypertension, Diabetes, and Cancer. This family of plants has been utilized for Anticonvulsant and Anxiolytic effects. The ongoing investigation is aimed to seek the antiepileptic potential of C. absus seed extracts in pentylenetetrazole-induced kindling mice. The seeds of C. absus were subjected to a sequential extraction process for the preparation of n-hexane, chloroform, methanol, and aqueous extracts. The PTZ-induced kindling model was employed to assess the antiepileptic activity of each extract. Seizure activity and antioxidant biomarkers in the brain tissue such as levels of CAT, SOD, tGSH, and MDA were assessed. Mechanism of action was elucidated by Flumazenil. Through GC-MS analysis, the phytochemical components in the chloroform extract of C. absus were evaluated. The outcomes showed that C. absus extracts markedly reduced the seizure activity in kindling mice. The extracts exhibited significant Antioxidant properties by enhancing the levels of antioxidant biomarkers in the brain tissue such as CAT, SOD, and tGSH, and decreasing the MDA level. The results demonstrated that C. absus extracts showed antiepileptic effects may be via GABA pathway. According to the results of this investigation, C. absus has significant antiepileptic potential in PTZ-induced kindling mice via GABA pathway modulation and combating reactive oxygen species.

4.
Inflammopharmacology ; 31(3): 1241-1256, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37005957

ABSTRACT

Traditional use of Cassia absus as an anti-inflammatory in conjunctivitis and bronchitis is well reported. Owing to its anti-inflammatory potential, the current study appraised in vivo anti-arthritic activity of n-hexane and aqueous extracts of Cassia absus seeds (200 mg/kg) using Complete Freund's Adjuvant (CFA) rat model of arthritis. Changes in paw size (mm), joint diameter (mm), and pain response (sec) were recorded at the baseline and then after CFA induction at the interval of 4 days till the 28th day. Blood samples of anesthetized rats were collected for the estimation of hematological, oxidative, and inflammatory biomarkers. Results showed percent inhibition in paw edema (45.09% and 60.79%) with both n-hexane and aqueous extracts, respectively. Significant reduction in paw size and ankle joint diameter (P < 0.01) was seen in extracts treated rats. Erythrocyte Sedimentation rate, C-Reactive Protein, White Blood Cell levels significantly lowered, and Hemoglobin, Platelets and Red Blood Cell count significantly increased post-treatments. Superoxide Dismutase, Catalase, and Glutathione were significantly improved (P < 0.0001) in treated groups as compared to CFA induced arthritic control. Real-time polymerase chain reaction investigation showed significant downregulation (P < 0.05) of Interleukin-1ß, Tumor Necrosis Factor-α, Interleukin-6, Cycloxygenase-2, Nuclear Factor-κB, Prostaglandin E Synthase 2, Interferon Gamma and upregulation of Interleukin-4, Interleukin-10 in both n-hexane and aqueous extract-treated groups. It is thereby concluded that Cassia absus can significantly attenuate CFA-induced arthritis by modulation of oxidative and inflammatory biomarkers.


Subject(s)
Arthritis, Experimental , Cassia , Rats , Animals , Interleukin-6/metabolism , NF-kappa B/metabolism , Tumor Necrosis Factor-alpha/metabolism , Freund's Adjuvant/pharmacology , Interleukin-10/metabolism , Interleukin-4/metabolism , Cassia/metabolism , Up-Regulation , Down-Regulation , Interleukin-1beta/metabolism , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Interferon-gamma/metabolism , Anti-Inflammatory Agents/pharmacology , Biomarkers , Arthritis, Experimental/chemically induced , Arthritis, Experimental/drug therapy , Arthritis, Experimental/metabolism
5.
Antioxidants (Basel) ; 11(11)2022 Nov 12.
Article in English | MEDLINE | ID: mdl-36421417

ABSTRACT

This study aimed to assess the potential of Lactuca serriola (Asteraceae) seed n-hexane, chloroform, methanol, and aqueous extracts as anticonvulsant, sedative, anticonvulsant and antiepileptic agents in Swiss albino mice. Different doses of each extract were evaluated for the anxiolytic potential using the hole-board, the elevated plus maze and the light/dark test. A phenobarbitone-induced sleep test was employed for the evaluation of sedative potential. Acute anticonvulsant activity was evaluated by picrotoxin and strychnine-induced convulsion models. All extracts significantly reduced the number of head dips where n-hexane extract (400 mg/kg) showed 96.34% reduction in the tendency of head dipping when compared with the control. Mice treated with extracts preferred elevated plus maze open arms and were shown to lack open arms evasion, especially n-hexane extract (400 mg/kg)-which showed 456.14%-increased the duration of open arm stay with the respective control group. By reducing sleep latency and greatly lengthening sleep duration, L. serriola enhanced the effects of barbiturate-induced sleep. A significant increase in convulsion latency and decrease in convulsions induced by picrotoxin and strychnine duration was observed in all extract-treated groups. All the extracts exhibited anti-epileptogenic potential as the seizure score in pentylenetetrazol (PTZ)-induced kindling in mice was reduced significantly. Maximum protection was afforded by chloroform extract that reduced the seizure score by 79.93% compared with the PTZ group. Chloroform executed antioxidant effect by elevating super oxide dismutase (SOD) by 126%, catalase (CAT) by 83.53%, total glutathione (tGSH) by 149%, and reducing malondialdhyde (MDA) levels by 36.49% in the brain tissues that is further consolidated by histopathological examination. Metabolic profiling of the most active chloroform extract using Gas chromatography coupled with mass showed the presence of 16 compounds. This anti-epileptic activity was further confirmed via in silico molecular modelling studies in the active site Gamma-aminobutyric acid aminotransferase (GABA-AT) where all of the tested metabolites illustrated a potent inhibitory potential towards GABA-AT with hexadecanoic acid, 15-methyl-, methyl ester followed by octadecanoic acid, methyl ester showed the best fitting. The results indicated the possible anxiolytic and anti-epileptogenic potential of the plant and further consolidated the ethnopharmacological use of L. serriola seeds.

6.
Pak J Pharm Sci ; 35(6(Special)): 1705-1711, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36861232

ABSTRACT

Medicinal plants are becoming popular choice for treatment of chronic disease conditions. Cassia absus plant parts have been traditionally used to treat inflammatory conditions. This study was designed for evaluating anti-arthritic, anti-nociceptive and anti-inflammatory potential of Cassia absus seeds. n- hexane, methanol, chloroform and aqueous extracts were prepared to be appraised for identification and quantitative determination of various phytochemicals. All the extracts were evaluated for anti-arthritic activity via protein denaturation, anti-nociceptive activity by hot plate method and anti-inflammatory potential through Carrageenan induced paw edema. Three doses; 100, 200 and 300mg/kg of each extract were given to Wistar rats. The results of the quantitative analysis revealed that Aqueous and n-hexane extracts contained the highest total flavonoid (104.2±0.24mg QE/g) and phenolic contents (187.4±0.65mg GA/g) respectively. All the extracts exhibited decrease in protein denaturation (n-hexane 66.66%, methanol 59.42%, chloroform 65.21% and aqueous extract 89.85%). Significant increase in mean latency time (secs) was observed in n-hexane, methanol and aqueous extract treated rats as compared to normal rats. All four extracts caused significant reduction in paw inflammation as compared to carrageenan control. It is therefore concluded that all the extracts of Cassia absus possessed significant anti-arthritic, anti-nociceptive and anti-inflammatory potential.


Subject(s)
Cassia , Animals , Rats , Rats, Wistar , Carrageenan , Chloroform , Methanol , Anti-Inflammatory Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...